Immunitas Therapeutics

Immunitas Therapeutics

Biotechnology, 830 Winter St Ste 2, Waltham, Massachusetts, 02451, United States, 11-50 Employees

immunitastx.com

  • twitter
  • LinkedIn

Who is IMMUNITAS THERAPEUTICS

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas programs are derived from a cross-functional, highly integrated, single cell geno...

Read More

map
  • 830 Winter St Ste 2, Waltham, Massachusetts, 02451, United States Headquarters: 830 Winter St Ste 2, Waltham, Massachusetts, 02451, United States
  • 2019 Date Founded: 2019
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 3821

checked-icon Does something look wrong? Fix it. | View contact records from IMMUNITAS THERAPEUTICS

Immunitas Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Immunitas Therapeutics

Answer: Immunitas Therapeutics's headquarters are located at 830 Winter St Ste 2, Waltham, Massachusetts, 02451, United States

Answer: Immunitas Therapeutics's official website is https://immunitastx.com

Answer: Immunitas Therapeutics's revenue is $1 Million to $5 Million

Answer: Immunitas Therapeutics's SIC: 3821

Answer: Immunitas Therapeutics has 11-50 employees

Answer: Immunitas Therapeutics is in Biotechnology

Answer: Immunitas Therapeutics contact info: Phone number: Website: https://immunitastx.com

Answer: Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access